Lowest Price Guaranteed
Pages
297
Last Updated
July 2026
View Count
23287
1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Inclusions and Exclusions
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID-19 Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT-SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Overview of Lipids
5.3. Introduction to Lipid Nanoparticles
5.3.1. Types of Lipid Nanoparticles
5.3.1.1. Solid Lipid Nanoparticles
5.3.1.2. Nanostructured Lipid Carriers
5.3.2. Advantages of Lipid Nanoparticles
5.3.3. Applications of Lipid Nanoparticles in Pharmaceutical Industry
5.3.3.1. Cancer Treatment
5.3.3.2. Gene Therapy
5.3.3.3. Vaccine Development
5.3.3.4. Medical Imaging / Diagnostics
5.3.3.5. Additional Applications
5.4. Challenges Associated with Lipid Nanoparticle Manufacturing
5.5. Need for Outsourcing Lipid Nanoparticle Manufacturing
5.6. Concluding Remarks
6. LIPID NANOPARTICLES: SERVICE PROVIDERS LANDSCAPE
6.1. Chapter Overview
6.2. Lipid Nanoparticle Manufacturing: List of Service Providers
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Company Size and Location of Headquarters
6.2.5. Analysis by Location of Lipid Nanoparticle Manufacturing Facility
6.2.6. Analysis by Scale of Operation
6.2.7. Analysis by Type of Molecule Delivered
6.2.8. Analysis by Therapeutic Area
6.2.9. Analysis by Type of Additional Services Offered
7. LIPID NANOPARTICLES: TECHNOLOGY LANDSCAPE
7.1. Chapter Overview
7.2. Lipid Nanoparticle: Technology Landscape
7.2.1. Analysis by Type of Formulation Method
7.2.2. Analysis by Type of Molecule Delivered
7.2.3. Analysis by Compatible Dosage Form
7.2.4. Analysis by Routes of Administration
7.2.5. Analysis by Therapeutic Area
7.3. Lipid Nanoparticle Technologies: List of Technology Developers
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Analysis by Company Size and Location of Headquarters
7.3.5. Analysis by Business Model
7.3.6. Most Active Players: Analysis by Number of Technologies
8. OTHER TYPES OF LIPIDS: SERVICE PROVIDERS LANDSCAPE
8.1. Chapter Overview
8.2. Other Types of Lipids: List of Service Providers
8.2.1. Analysis by Year of Establishment
8.2.2. Analysis by Company Size
8.2.3. Analysis by Location of Headquarters
8.2.4. Analysis by Company Size and Location of Headquarters
8.2.5. Analysis by Location of Manufacturing Facility
8.2.6. Analysis by Scale of Operation
8.2.7. Analysis by Type of Lipid Manufactured
8.2.8. Analysis by Scale of Operation and Type of Lipid Manufactured
8.2.9. Analysis by Type of Product
8.2.10. Analysis by Type of Additional Services Offered
8.2.11. Analysis by Type of Product and Type of Additional Services Offered
9. COMPANY COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. Lipid Nanoparticle Manufacturing Service Providers: Company Competitiveness Analysis
9.4.1. Company Competitiveness Analysis: Small Players
9.4.2. Company Competitiveness Analysis: Mid-sized Players
9.4.3. Company Competitiveness Analysis: Large and Very Large Players
10. TECHNOLOGY COMPETITIVENESS ANALYSIS
10.1. Chapter Overview
10.2. Assumptions and Key Parameters
10.3. Methodology
10.4. Lipid Nanoparticle Technologies: Competitiveness Analysis
10.4.1. Technology Competitiveness Analysis: Players based in North America
10.4.2. Technology Competitiveness Analysis: Players based in Europe and Asia-Pacific
11. COMPANY PROFILES: SERVICE PROVIDERS OF LIPID NANOPARTICLES
11.1. Chapter Overview
11.2. Curia
11.2.1. Company Overview
11.2.2. Service Portfolio
11.2.3. Recent Developments and Future Outlook
11.3. Emergent BioSolutions
11.3.1. Company Overview
11.3.2. Service Portfolio
11.3.3. Recent Developments and Future Outlook
11.4. EUROAPI
11.4.1. Company Overview
11.4.2. Service Portfolio
11.4.3. Recent Developments and Future Outlook
11.5. Evonik
11.5.1. Company Overview
11.5.2. Service Portfolio
11.5.3. Recent Developments and Future Outlook
11.6. Curapath
11.6.1. Company Overview
11.6.2. Service Portfolio
11.7. BIOVECTRA
11.7.1. Company Overview
11.7.2. Service Portfolio
11.8. Precision NanoSystems
11.8.1. Company Overview
11.8.2. Service Portfolio
12. COMPANY PROFILES: LIPID NANOPARTICLE TECHNOLOGY DEVELOPERS
12.1. Chapter Overview
12.2. Ascendia Pharmaceuticals
12.2.1. Company Overview
12.2.2. Lipid Nanoparticle Technology Portfolio
12.2.3. Recent Developments and Future Outlook
12.3. leon-nanodrugs
12.3.1. Company Overview
12.3.2. Lipid Nanoparticle Technology Portfolio
12.3.3. Recent Developments and Future Outlook
12.4. Pantherna Therapeutics
12.4.1. Company Overview
12.4.2. Lipid Nanoparticle Technology Portfolio
12.4.3. Recent Developments and Future Outlook
12.5. TLC Biosciences
12.5.1. Company Overview
12.5.2. Lipid Nanoparticle Technology Portfolio
12.5.3. Recent Developments and Future Outlook
12.6. Acuitas Therapeutics
12.6.1. Company Overview
12.6.2. Lipid Nanoparticle Technology Portfolio
12.7. Integrated Nanotherapeutics
12.7.1. Company Overview
12.7.2. Lipid Nanoparticle Technology Portfolio
12.8. Matinas BioPharma
12.8.1. Company Overview
12.8.2. Lipid Nanoparticle Technology Portfolio
13. COMPANY PROFILES: SERVICE PROVIDERS OF OTHER TYPES OF LIPIDS
13.1. Chapter Overview
13.2. Avanti Polar Lipids
13.2.1. Company Overview
13.2.2. Service Portfolio
13.2.3. Recent Developments and Future Outlook
13.3. CordenPharma
13.3.1. Company Overview
13.3.2. Service Portfolio
13.3.3. Recent Developments and Future Outlook
13.4. FUJIFILM
13.4.1. Company Overview
13.4.2. Service Portfolio
13.4.3. Recent Developments and Future Outlook
13.5. Merck
13.5.1. Company Overview
13.5.2. Service Portfolio
13.5.3. Recent Developments and Future Outlook
13.6. FormuMax Scientific
13.6.1. Company Overview
13.6.2. Service Portfolio
13.7. Creative Biolabs
13.7.1. Company Overview
13.7.2. Service Portfolio
13.8. Fresenius Kabi
13.8.1. Company Overview
13.8.2. Service Portfolio
14. PARTNERSHIPS AND COLLABORATIONS
14.1. Chapter Overview
14.2. Partnership Models
14.3. Lipid Nanoparticle Services and Technologies: List of Partnerships and Collaborations
14.3.1. Analysis by Year of Partnership
14.3.2. Analysis by Type of Partnership
14.3.3. Analysis by Year and Type of Partnership
14.3.4. Analysis by Type of Molecule
14.3.5. Analysis by Therapeutic Area
14.3.6. Analysis by Type of Partner
14.3.7. Most Active Players: Analysis by Number of Partnerships
14.3.8. Analysis by Geography
14.3.8.1. Intracontinental and Intercontinental Deals
14.3.8.2. International and Local Deals
15. LIKELY PARTNER ANALYSIS
15.1. Chapter Overview
15.2. Methodology
15.3. mRNA Drug Developers: Potential Strategic Partners in North America
15.4. mRNA Drug Developers: Potential Strategic Partners in Europe and Asia-Pacific
16. MAKE VERSUS BUY DECISION FRAMEWORK
16.1. Chapter Overview
16.2. Assumptions and Key Parameters
16.3. Lipid Nanoparticle Service Providers: Make versus Buy Decision Making Framework
16.3.1. Scenario 1
16.3.2. Scenario 2
16.3.3. Scenario 3
16.3.4. Scenario 4
16.4. Concluding Remarks
17. CAPACITY ANALYSIS
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Global Installed Lipid Nanoparticle Contract Manufacturing Capacity
17.3.1. Analysis by Range of Installed Capacity
17.3.2. Analysis by Company Size
17.3.3. Analysis by Scale of Operation
17.3.4. Analysis by Location of Manufacturing Facility
17.3.4.1. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in North America
17.3.4.2. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in Europe
17.3.4.3. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in Asia-Pacific
17.3.5. Concluding Remarks
18. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
18.1. Chapter Overview
18.2. Market Drivers
18.3. Market Restraints
18.4. Market Opportunities
18.5. Market Challenges
18.6. Conclusion
19. GLOBAL LIPID NANOPARTICLE MANUFACTURING MARKET
19.1. Chapter Overview
19.2. Assumptions and Methodology
19.3. Global Lipid Nanoparticle Manufacturing Market, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
19.3.1. Scenario Analysis
19.3.1.1. Conservative Scenario
19.3.1.2. Optimistic Scenario
19.4. Key Market Segmentations
20. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF LIPID NANOPARTICLE
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of Lipid Nanoparticle
20.3.1. Lipid Nanoparticle Manufacturing Market for Solid Lipid Nanoparticles, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
20.3.2. Lipid Nanoparticle Manufacturing Market for Nanostructured Lipid Carriers, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
20.4. Data Triangulation and Validation
21. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF MOLECULE DELIVERED
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of Molecule Delivered
21.3.1. Lipid Nanoparticle Manufacturing Market for Nucleic Acids, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
21.3.2. Lipid Nanoparticle Manufacturing Market for Small Molecules, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
21.3.3. Lipid Nanoparticle Manufacturing Market for Peptides / Proteins, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
21.3.4. Lipid Nanoparticle Manufacturing Market for Others, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
21.4. Data Triangulation and Validation
22. LIPID NANOPARTICLE MANUFACTURING MARKET, BY COMPANY SIZE
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Lipid Nanoparticle Manufacturing Market: Distribution by Company Size
22.3.1. Lipid Nanoparticle Manufacturing Market for Small Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
22.3.2. Lipid Nanoparticle Manufacturing Market for Mid-sized Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
22.3.3. Lipid Nanoparticle Manufacturing Market for Very Large and Lare Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
22.4. Data Triangulation and Validation
23. LIPID NANOPARTICLE MANUFACTURING MARKET, BY THERAPEUTIC AREA
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Lipid Nanoparticle Manufacturing Market: Distribution by Therapeutic Area
23.3.1. Lipid Nanoparticle Manufacturing Market for Infectious Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
23.3.2. Lipid Nanoparticle Manufacturing Market for Oncological Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
23.3.3. Lipid Nanoparticle Manufacturing Market for Blood Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
23.3.4. Lipid Nanoparticle Manufacturing Market for Rare Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
23.3.5. Lipid Nanoparticle Manufacturing Market for Other Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
23.4. Data Triangulation and Validation
24. LIPID NANOPARTICLE MANUFACTURING MARKET, BY END-USER
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Lipid Nanoparticle Manufacturing Market: Distribution by End-user
24.3.1. Lipid Nanoparticle Manufacturing Market for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
24.3.2. Lipid Nanoparticle Manufacturing Market for Academic and Research Institutes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
24.3.3. Lipid Nanoparticle Manufacturing Market for Other End-users, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
24.4. Data Triangulation and Validation
25. LIPID NANOPARTICLE MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Lipid Nanoparticle Manufacturing Market: Distribution by Key Geographical Regions
25.3.1. Lipid Nanoparticle Manufacturing Market in North America, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
25.3.2. Lipid Nanoparticle Manufacturing Market in Europe, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
25.3.3. Lipid Nanoparticle Manufacturing Market in Asia-Pacific, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
25.3.4. Lipid Nanoparticle Manufacturing Market in Rest of the World, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
25.4. Market Dynamics Assessment
25.4.1. Revenue Shift Analysis
25.4.2. Penetration Growth (P-G) Matrix
25.5. Data Triangulation and Validation
26. LIPID NANOPARTICLE MANUFACTURING MARKET: NORTH AMERICA
26.1. Lipid Nanoparticle Manufacturing Market in North America: Distribution by Type of Lipid Nanoparticle
26.1.1. Lipid Nanoparticle Manufacturing Market in North America for Solid Lipid Nanoparticles, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
26.1.2. Lipid Nanoparticle Manufacturing Market in North America for Nanostructured Lipid Carriers, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
26.2. Lipid Nanoparticle Manufacturing Market in North America: Distribution by Type of Molecule Delivered
26.2.1. Lipid Nanoparticle Manufacturing Market in North America for Nucleic Acids, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
26.2.2. Lipid Nanoparticle Manufacturing Market in North America for Small Molecules, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
26.2.3. Lipid Nanoparticle Manufacturing Market in North America for Peptides / Proteins, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
26.2.4. Lipid Nanoparticle Manufacturing Market in North America for Others, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
26.3. Lipid Nanoparticle Manufacturing Market in North America: Distribution by Company Size
26.3.1. Lipid Nanoparticle Manufacturing Market in North America for Small Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
26.3.2. Lipid Nanoparticle Manufacturing Market in North America for Mid-sized Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
26.3.3. Lipid Nanoparticle Manufacturing Market in North America for Very Large and Large Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
26.4. Lipid Nanoparticle Manufacturing Market in North America: Distribution by Therapeutic Area
26.4.1. Lipid Nanoparticle Manufacturing Market in North America for Infectious Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
26.4.2. Lipid Nanoparticle Manufacturing Market in North America for Oncological Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
26.4.3. Lipid Nanoparticle Manufacturing Market in North America for Blood Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
26.4.4. Lipid Nanoparticle Manufacturing Market in North America for Rare Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
26.4.5. Lipid Nanoparticle Manufacturing Market in North America for Other Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
26.5. Lipid Nanoparticle Manufacturing Market in North America: Distribution by End-user
26.5.1. Lipid Nanoparticle Manufacturing Market in North America for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
26.5.2. Lipid Nanoparticle Manufacturing Market in North America for Academic and Research Institutes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
26.5.3. Lipid Nanoparticle Manufacturing Market in North America for Other End-users, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
27. LIPID NANOPARTICLE MANUFACTURING MARKET: EUROPE
27.1. Lipid Nanoparticle Manufacturing Market in Europe: Distribution by Type of Lipid Nanoparticle
27.1.1. Lipid Nanoparticle Manufacturing Market in Europe for Solid Lipid Nanoparticles, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
27.1.2. Lipid Nanoparticle Manufacturing Market in Europe for Nanostructured Lipid Carriers, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
27.2. Lipid Nanoparticle Manufacturing Market in Europe: Distribution by Type of Molecule Delivered
27.2.1. Lipid Nanoparticle Manufacturing Market in Europe for Nucleic Acids, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
27.2.2. Lipid Nanoparticle Manufacturing Market in Europe for Small Molecules, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
27.2.3. Lipid Nanoparticle Manufacturing Market in Europe for Peptides / Proteins, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
27.2.4. Lipid Nanoparticle Manufacturing Market in Europe for Others, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
27.3. Lipid Nanoparticle Manufacturing Market in Europe: Distribution by Company Size
27.3.1. Lipid Nanoparticle Manufacturing Market in Europe for Small Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
27.3.2. Lipid Nanoparticle Manufacturing Market in Europe for Mid-sized Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
27.3.3. Lipid Nanoparticle Manufacturing Market in Europe for Very Large and Large Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
27.4. Lipid Nanoparticle Manufacturing Market in Europe: Distribution by Therapeutic Area
27.4.1. Lipid Nanoparticle Manufacturing Market in Europe for Infectious Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
27.4.2. Lipid Nanoparticle Manufacturing Market in Europe for Oncological Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
27.4.3. Lipid Nanoparticle Manufacturing Market in Europe for Blood Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
27.4.4. Lipid Nanoparticle Manufacturing Market in Europe for Rare Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
27.4.5. Lipid Nanoparticle Manufacturing Market in Europe for Other Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
27.5. Lipid Nanoparticle Manufacturing Market in Europe: Distribution by End-user
27.5.1. Lipid Nanoparticle Manufacturing Market in Europe for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
27.5.2. Lipid Nanoparticle Manufacturing Market in Europe for Academic and Research Institutes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
27.5.3. Lipid Nanoparticle Manufacturing Market in Europe for Other End-users, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
28. LIPID NANOPARTICLE MANUFACTURING MARKET: ASIA-PACIFIC
28.1. Lipid Nanoparticle Manufacturing Market in Asia-Pacific: Distribution by Type of Lipid Nanoparticle
28.1.1. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Solid Lipid Nanoparticles, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
28.1.2. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Nanostructured Lipid Carriers, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
28.2. Lipid Nanoparticle Manufacturing Market in Asia-Pacific: Distribution by Type of Molecule Delivered
28.2.1. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Nucleic Acids, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
28.2.2. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Small Molecules, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
28.2.3. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Peptides / Proteins, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
28.2.4. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Others, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
28.3. Lipid Nanoparticle Manufacturing Market in Asia-Pacific: Distribution by Company Size
28.3.1. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Small Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
28.3.2. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Mid-sized Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
28.3.3. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Very Large and Large Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
28.4. Lipid Nanoparticle Manufacturing Market in Asia-Pacific: Distribution by Therapeutic Area
28.4.1. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Infectious Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
28.4.2. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Oncological Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
28.4.3. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Blood Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
28.4.4. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Rare Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
28.4.5. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Other Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
28.5. Lipid Nanoparticle Manufacturing Market in Asia-Pacific: Distribution by End-user
28.5.1. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
28.5.2. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Academic and Research Institutes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
28.5.3. Lipid Nanoparticle Manufacturing Market in Asia-Pacific for Other End-users, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
29. LIPID NANOPARTICLE MANUFACTURING MARKET: REST OF THE WORLD
29.1. Lipid Nanoparticle Manufacturing Market in Rest of the World: Distribution by Type of Lipid Nanoparticle
29.1.1. Lipid Nanoparticle Manufacturing Market in Rest of the World for Solid Lipid Nanoparticles, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
29.1.2. Lipid Nanoparticle Manufacturing Market in Rest of the World for Nanostructured Lipid Carriers, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
29.2. Lipid Nanoparticle Manufacturing Market in Rest of the World: Distribution by Type of Molecule Delivered
29.2.1. Lipid Nanoparticle Manufacturing Market in Rest of the World for Nucleic Acids, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
29.2.2. Lipid Nanoparticle Manufacturing Market in Rest of the World for Small Molecules, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
29.2.3. Lipid Nanoparticle Manufacturing Market in Rest of the World for Peptides / Proteins, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
29.2.4. Lipid Nanoparticle Manufacturing Market in Rest of the World for Others, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
29.3. Lipid Nanoparticle Manufacturing Market in Rest of the World: Distribution by Company Size
29.3.1. Lipid Nanoparticle Manufacturing Market in Rest of the World for Small Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
29.3.2. Lipid Nanoparticle Manufacturing Market in Rest of the World for Mid-sized Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
29.3.3. Lipid Nanoparticle Manufacturing Market in Rest of the World for Very Large and Large Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
29.4. Lipid Nanoparticle Manufacturing Market in Rest of the World: Distribution by Therapeutic Area
29.4.1. Lipid Nanoparticle Manufacturing Market in Rest of the World for Infectious Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
29.4.2. Lipid Nanoparticle Manufacturing Market in Rest of the World for Oncological Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
29.4.3. Lipid Nanoparticle Manufacturing Market in Rest of the World for Blood Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
29.4.4. Lipid Nanoparticle Manufacturing Market in Rest of the World for Rare Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
29.4.5. Lipid Nanoparticle Manufacturing Market in Rest of the World for Other Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
29.5. Lipid Nanoparticle Manufacturing Market in Rest of the World: Distribution by End-user
29.5.1. Lipid Nanoparticle Manufacturing Market in Rest of the World for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
29.5.2. Lipid Nanoparticle Manufacturing Market in Rest of the World for Academic and Research Institutes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
29.5.3. Lipid Nanoparticle Manufacturing Market in Rest of the World for Other End-users, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Detailed information on Chapters 26 to 29 is available in the Excel Data Packs shared along with the report.
30. CONCLUSION
31. EXECUTIVE INSIGHTS
31.1. Chapter Overview
31.2. Company A
31.2.1. Company Snapshot
31.2.2. Interview Transcript: Founder and Chief Executive Officer
31.3. Company B
31.3.1. Company Snapshot
31.3.2. Interview Transcript: Former Director, Process Development, Chemistry and Former Acting Manager, Biotech Process Development
31.4. Company C
31.4.1. Company Snapshot
31.4.2. Interview Transcript: Formulation Scientist
31.5. Company D
31.5.1. Company Snapshot
31.5.2. Interview Transcript: Chief Executive Officer and Chief Operating Officer
31.6. Company E
31.6.1. Company Snapshot
31.6.2. Interview Transcript: Chief Executive Officer
31.7. Company F
31.7.1. Company Snapshot
31.7.2. Interview Transcript: Chief Executive Officer
31.8. Company G
31.8.1. Company Snapshot
31.8.2. Interview Transcript: Founder, Chair and Chief Executive Officer
31.9. Company H
31.9.1. Company Snapshot
31.9.2. Interview Transcript: Chief Executive Officer
31.10. Company I
31.10.1. Company Snapshot
31.10.2. Interview Transcript: Chief Executive Officer and Commercial Officer
31.11. Company J
31.11.1. Company Snapshot
31.11.2. Interview Transcript: Board Chair and Co-Founder; Chief Scientific Officer and Co-Founder
31.12. Company K
31.12.1. Company Snapshot
31.12.2. Interview Transcript: Executive Director and Head of Next Generation Drug Delivery
31.13. Company L
31.13.1. Company Snapshot
31.13.2. Interview Transcript: Patent Prosecution Partner and IP Litigation Partner
31.14. Company M
31.14.1. Company Snapshot
31.14.2. Interview Transcript: Lipid Nanoparticle Consultant
32. APPENDIX I: TABULATED DATA
33. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Research Methodology: Research Assumptions
Figure 2.2 Research Methodology: Project Methodology
Figure 2.3 Research Methodology: Forecast Methodology
Figure 2.4 Research Methodology: Robust Quality Control
Figure 2.5 Research Methodology: Key Market Segmentations
Figure 4.1 Executive Summary: Lipid Nanoparticle Manufacturing Service Providers Market Landscape
Figure 4.2 Executive Summary: Lipid Nanoparticle Technology Developers Market Landscape
Figure 4.3 Executive Summary: Service Providers of Other Types of Lipids Market Landscape
Figure 4.4 Executive Summary: Partnerships and Collaborations
Figure 4.5 Executive Summary: Capacity Analysis
Figure 4.6 Executive Summary: Market Sizing and Opportunity Analysis
Figure 5.1 Classification of Lipids
Figure 5.2 Historical Development of Lipid Nanoparticles
Figure 5.3 Orientation of Drug in Solid Lipid Nanoparticles and Nanostructured Lipid Carriers
Figure 5.4 Commonly Outsourced Lipid Nanoparticle Contract Manufacturing Services
Figure 6.1 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Year of Establishment
Figure 6.2 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Company Size
Figure 6.3 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Location of Headquarters
Figure 6.4 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Company Size and Location of Headquarters
Figure 6.5 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Location of Lipid Nanoparticle Manufacturing Facility
Figure 6.6 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Scale of Operation
Figure 6.7 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Type of Molecule Delivered
Figure 6.8 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Therapeutic Area
Figure 6.9 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Type of Additional Services Offered
Figure 7.1 Lipid Nanoparticle Technologies: Distribution by Type of Formulation Method
Figure 7.2 Lipid Nanoparticle Technologies: Distribution by Type of Molecule Delivered
Figure 7.3 Lipid Nanoparticle Technologies: Distribution by Compatible Dosage Form
Figure 7.4 Lipid Nanoparticle Technologies: Distribution by Route of Administration
Figure 7.5 Lipid Nanoparticle Technologies: Distribution by Therapeutic Area
Figure 7.6 Lipid Nanoparticle Technology Developers: Distribution by Year of Establishment
Figure 7.7 Lipid Nanoparticle Technology Developers: Distribution by Company Size
Figure 7.8 Lipid Nanoparticle Technology Developers: Distribution by Location of Headquarters
Figure 7.9 Lipid Nanoparticle Technology Developers: Distribution by Company Size and Location of Headquarters
Figure 7.10 Lipid Nanoparticle Technology Developers: Distribution by Business Model
Figure 7.11 Most Active Players: Distribution by Number of Technologies
Figure 8.1 Service Providers of Other Types of Lipids: Distribution by Year of Establishment
Figure 8.2 Service Providers of Other Types of Lipids: Distribution by Company Size
Figure 8.3 Service Providers of Other Types of Lipids: Distribution by Location of Headquarters
Figure 8.4 Service Providers of Other Types of Lipids: Distribution by Company Size and Location of Headquarters
Figure 8.5 Service Providers of Other Types of Lipids: Distribution by Location of Manufacturing Facility
Figure 8.6 Service Providers of Other Types of Lipids: Distribution by Scale of Operation
Figure 8.7 Service Providers of Other Types of Lipids: Distribution by Type of Lipid Manufactured
Figure 8.8 Service Providers of Other Types of Lipids: Distribution by Scale of Operation and Type of Lipid Manufactured
Figure 8.9 Service Providers of Other Types of Lipids: Distribution by Type of Product
Figure 8.10 Service Providers of Other Types of Lipids: Distribution by Type of Additional Services Offered
Figure 8.11 Service Providers of Other Types of Lipids: Distribution by Type of Product and Type of Additional Services Offered
Figure 9.1 Company Competitiveness Analysis: Small Players
Figure 9.2 Company Competitiveness Analysis: Mid-sized Players
Figure 9.3 Company Competitiveness Analysis: Large and Very Large Players
Figure 10.1 Technology Competitiveness Analysis: Lipid Nanoparticle Manufacturing Technologies Offered by Players based in North America
Figure 10.2 Technology Competitiveness Analysis: Lipid Nanoparticle Manufacturing Technologies Offered by Players based in Europe and Asia-Pacific
Figure 14.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2019
Figure 14.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 14.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 14.4 Partnerships and Collaborations: Distribution by Type of Molecule
Figure 14.5 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 14.6 Partnerships and Collaborations: Distribution by Type of Partner
Figure 14.7 Most Active Players: Distribution by Number of Partnerships
Figure 14.8 Partnerships and Collaborations: Intracontinental and Intercontinental Deals
Figure 14.9 Partnerships and Collaborations: International and Local Deals
Figure 15.1 Spider-web Analysis: Potential Strategic Partners in North America
Figure 15.2 Spider-web Analysis: Potential Strategic Partners in Europe and Asia-Pacific
Figure 16.1 Make versus Buy Decision Making Framework
Figure 16.2 Make versus Buy Decision Making: Possible Scenarios
Figure 17.1 Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Distribution by Range of Installed Capacity (Liters)
Figure 17.2 Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Distribution by Company Size
Figure 17.3 Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Distribution by Scale of Operation
Figure 17.4 Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Distribution by Location of Manufacturing Facility
Figure 17.5 Installed Lipid Nanoparticle Contract Manufacturing Capacity in North America
Figure 17.6 Installed Lipid Nanoparticle Contract Manufacturing Capacity in Europe
Figure 17.7 Installed Lipid Nanoparticle Contract Manufacturing Capacity in Asia-Pacific
Figure 18.1 Market Drivers
Figure 18.2 Market Restraints
Figure 18.3 Market Opportunities
Figure 18.4 Market Challenges
Figure 19.1 Global Lipid Nanoparticle Manufacturing Market, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 19.2 Global Lipid Nanoparticle Manufacturing Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Billion)
Figure 19.3 Global Lipid Nanoparticle Manufacturing Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Billion)
Figure 20.1 Lipid Nanoparticle Manufacturing Market: Distribution by Type of Lipid Nanoparticle
Figure 20.2 Lipid Nanoparticle Manufacturing Market for Solid Lipid Nanoparticles, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 20.3 Lipid Nanoparticle Manufacturing Market for Nanostructured Lipid Carriers, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.1 Lipid Nanoparticle Manufacturing Market: Distribution by Type of Molecule Delivered
Figure 21.2 Lipid Nanoparticle Manufacturing Market for Nucleic Acids, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.3 Lipid Nanoparticle Manufacturing Market for Small Molecules, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.4 Lipid Nanoparticle Manufacturing Market for Peptides / Proteins, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.5 Lipid Nanoparticle Manufacturing Market for Others, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 22.1 Lipid Nanoparticle Manufacturing Market: Distribution by Company Size
Figure 22.2 Lipid Nanoparticle Manufacturing Market for Small Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 22.3 Lipid Nanoparticle Manufacturing Market for Mid-sized Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 22.4 Lipid Nanoparticle Manufacturing Market for Very Large and Large Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.1 Lipid Nanoparticle Manufacturing Market: Distribution by Therapeutic Area
Figure 23.2 Lipid Nanoparticle Manufacturing Market for Infectious Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.3 Lipid Nanoparticle Manufacturing Market for Oncological Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.4 Lipid Nanoparticle Manufacturing Market for Blood Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.5 Lipid Nanoparticle Manufacturing Market for Rare Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.6 Lipid Nanoparticle Manufacturing Market for Other Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.1 Lipid Nanoparticle Manufacturing Market: Distribution by End-user
Figure 24.2 Lipid Nanoparticle Manufacturing Market for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.3 Lipid Nanoparticle Manufacturing Market for Academic and Research Institutes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.4 Lipid Nanoparticle Manufacturing Market for Other End-users, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.1 Lipid Nanoparticle Manufacturing Market: Distribution by Key Geographical Regions
Figure 25.2 Lipid Nanoparticle Manufacturing Market in North America, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.3 Lipid Nanoparticle Manufacturing Market in Europe, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.4 Lipid Nanoparticle Manufacturing Market in Asia-Pacific, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.5 Lipid Nanoparticle Manufacturing Market in Rest of the World, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.6 Revenue Shift Analysis: Key Geographical Regions
Figure 25.7 Penetration Growth (P-G) Matrix: Key Geographical Regions
Figure 30.1 Concluding Remarks: Lipid Nanoparticle Manufacturing Service Providers Market Landscape
Figure 30.2 Concluding Remarks: Lipid Nanoparticle Technology Developers Market Landscape
Figure 30.3 Concluding Remarks: Service Providers of Other Types of Lipids Market Landscape
Figure 30.4 Concluding Remarks: Partnerships and Collaborations
Figure 30.5 Concluding Remarks: Capacity Analysis
Figure 30.6 Concluding Remarks: Market Forecast and Opportunity Analysis (I/II)
Figure 30.7 Concluding Remarks: Market Forecast and Opportunity Analysis (II/II)
Table 6.1 Lipid Nanoparticle Manufacturing: List of Service Providers
Table 6.2 Lipid Nanoparticle Manufacturing Service Providers: Information on Scale of Operation and Type of Molecule Delivered
Table 6.3 Lipid Nanoparticle Manufacturing Service Providers: Information on Therapeutic Area and Additional Services Offered
Table 7.1 Lipid Nanoparticle Technologies: Information on Formulation Method and Type of Molecule Delivered
Table 7.2 Lipid Nanoparticle Technologies: Information on Compatible Dosage Form and Routes of Administration
Table 7.3 Lipid Nanoparticle Technologies: Information on Therapeutic Area
Table 7.4 Lipid Nanoparticle Technologies: List of Technology Developers
Table 8.1 Other Types of Lipids: List of Service Providers
Table 8.2 Service Providers of Other Types of Lipids: Information on Scale of Operation and Type of Lipid Manufactured
Table 8.3 Service Providers of Other Types of Lipids: Information on Type of Product and Additional Services Offered
Table 11.1 Leading Service Providers of Lipid Nanoparticles: List of Companies Profiled
Table 11.2 Curia: Company Snapshot
Table 11.3 Curia: Manufacturing Service Portfolio for LNPs
Table 11.4 Curia: Recent Developments and Future Outlook
Table 11.5 Emergent BioSolutions: Company Snapshot
Table 11.6 Emergent BioSolutions: Manufacturing Service Portfolio for LNPs
Table 11.7 Emergent BioSolutions: Recent Developments and Future Outlook
Table 11.8 EUROAPI: Company Snapshot
Table 11.9 EUROAPI: Manufacturing Service Portfolio for LNPs
Table 11.10 EUROAPI: Recent Developments and Future Outlook
Table 11.11 Evonik: Company Snapshot
Table 11.12 Evonik: Manufacturing Service Portfolio for LNPs
Table 11.13 Evonik: Recent Developments and Future Outlook
Table 11.14 Curapath: Company Snapshot
Table 11.15 Curapath: Manufacturing Service Portfolio for LNPs
Table 11.16 BIOVECTRA: Company Snapshot
Table 11.17 BIOVECTRA: Manufacturing Service Portfolio for LNPs
Table 11.18 Precision NanoSystems: Company Snapshot
Table 11.19 Precision NanoSystems: Manufacturing Service Portfolio for LNPs
Table 12.1 Leading LNP Technology Providers: List of Companies Profiled
Table 12.2 Ascendia Pharmaceuticals: Company Snapshot
Table 12.3 Ascendia Pharmaceuticals: Lipid Nanoparticle Technology Portfolio
Table 12.4 Ascendia Pharmaceuticals: Recent Developments and Future Outlook
Table 12.5 leon-nanodrugs: Company Snapshot
Table 12.6 leon-nanodrugs: Lipid Nanoparticle Technology Portfolio
Table 12.7 leon-nanodrugs: Recent Developments and Future Outlook
Table 12.8 Pantherna Therapeutics: Company Snapshot
Table 12.9 Pantherna Therapeutics: Lipid Nanoparticle Technology Portfolio
Table 12.10 Pantherna Therapeutics: Recent Developments and Future Outlook
Table 12.11 TLC Biosciences: Company Snapshot
Table 12.12 TLC Biosciences: Lipid Nanoparticle Technology Portfolio
Table 12.13 TLC Biosciences: Recent Developments and Future Outlook
Table 12.14 Acuitas Therapeutics: Company Snapshot
Table 12.15 Acuitas Therapeutics: Lipid Nanoparticle Technology Portfolio
Table 12.16 Integrated Nanotherapeutics: Company Snapshot
Table 12.17 Integrated Nanotherapeutics: Lipid Nanoparticle Technology Portfolio
Table 12.18 Matinas BioPharma: Company Snapshot
Table 12.19 Matinas BioPharma: Lipid Nanoparticle Technology Portfolio
Table 13.1 Leading Service Providers of Other Types of Lipids: List of Companies Profiled
Table 13.2 Avanti Polar Lipids: Company Snapshot
Table 13.3 Avanti Polar Lipids: Manufacturing Service Portfolio for Other Types of Lipids
Table 13.4 Avanti Polar Lipids: Recent Developments and Future Outlook
Table 13.5 CordenPharma: Company Snapshot
Table 13.6 CordenPharma: Manufacturing Service Portfolio for Other Types of Lipids
Table 13.7 CordenPharma: Recent Developments and Future Outlook
Table 13.8 FUJIFILM: Company Snapshot
Table 13.9 FUJIFILM: Manufacturing Service Portfolio for Other Types of Lipids
Table 13.10 FUJIFILM: Recent Developments and Future Outlook
Table 13.11 Merck: Company Snapshot
Table 13.12 Merck: Manufacturing Service Portfolio for Other Types of Lipids
Table 13.13 Merck: Recent Developments and Future Outlook
Table 13.14 FormuMax Scientific: Company Snapshot
Table 13.15 FormuMax Scientific: Manufacturing Service Portfolio for Other Types of Lipids
Table 13.16 Creative Biolabs: Company Snapshot
Table 13.17 Creative Biolabs: Manufacturing Service Portfolio for Other Types of Lipids
Table 13.18 Fresenius Kabi: Company Snapshot
Table 13.19 Fresenius Kabi: Manufacturing Service Portfolio for Other Types of Lipids
Table 14.1 Lipid Nanoparticle Services and Technologies: List of Partnerships and Collaborations, Since 2019
Table 15.1 mRNA Drug Developers: Potential Strategic Partners in North America
Table 15.2 mRNA Drug Developers: Potential Strategic Partners in Europe and Asia-Pacific
Table 17.1 Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Average Capacity by Company Size (Sample Dataset)
Table 17.2 Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Total Capacity by Company Size (Liters)
Table 31.1 LIPOSOMA: Company Snapshot
Table 31.2 BIOVECTRA: Company Snapshot
Table 31.3 OZ Biosciences: Company Snapshot
Table 32.1 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Year of Establishment
Table 32.2 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Company Size
Table 32.3 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Location of Headquarters
Table 32.4 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Company Size and Location of Headquarters
Table 32.5 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Location of Lipid Nanoparticle Manufacturing Facility
Table 32.6 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Scale of Operation
Table 32.7 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Type of Molecule Delivered
Table 32.8 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Therapeutic Area
Table 32.9 Lipid Nanoparticle Manufacturing Service Providers: Distribution by Type of Additional Services Offered
Table 32.10 Lipid Nanoparticle Technologies: Distribution by Type of Formulation Method
Table 32.11 Lipid Nanoparticle Technologies: Distribution by Type of Molecule Delivered
Table 32.12 Lipid Nanoparticle Technologies: Distribution by Compatible Dosage Form
Table 32.13 Lipid Nanoparticle Technologies: Distribution by Route of Administration
Table 32.14 Lipid Nanoparticle Technologies: Distribution by Therapeutic Area
Table 32.15 Lipid Nanoparticle Technology Developers: Distribution by Year of Establishment
Table 32.16 Lipid Nanoparticle Technology Developers: Distribution by Company Size
Table 32.17 Lipid Nanoparticle Technology Developers: Distribution by Location of Headquarters
Table 32.18 Lipid Nanoparticle Technology Developers: Distribution by Company Size and Location of Headquarters
Table 32.19 Lipid Nanoparticle Technology Developers: Distribution by Business Model
Table 32.20 Most Active Players: Distribution by Number of Technologies
Table 32.21 Service Providers of Other Types of Lipids: Distribution by Year of Establishment
Table 32.22 Service Providers of Other Types of Lipids: Distribution by Company Size
Table 32.23 Service Providers of Other Types of Lipids: Distribution by Location of Headquarters
Table 32.24 Service Providers of Other Types of Lipids: Distribution by Company Size and Location of Headquarters
Table 32.25 Service Providers of Other Types of Lipids: Distribution by Location of Manufacturing Facility
Table 32.26 Service Providers of Other Types of Lipids: Distribution by Scale of Operation
Table 32.27 Service Providers of Other Types of Lipids: Distribution by Type of Lipid Manufactured
Table 32.28 Service Providers of Other Types of Lipids: Distribution by Scale of Operation and Type of Lipid Manufactured
Table 32.29 Service Providers of Other Types of Lipids: Distribution by Type of Product
Table 32.30 Service Providers of Other Types of Lipids: Distribution by Type of Additional Services Offered
Table 32.31 Service Providers of Other Types of Lipids: Distribution by Type of Product and Type of Services Offered
Table 32.32 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2019
Table 32.33 Partnerships and Collaborations: Distribution by Type of Partnership
Table 32.34 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 32.35 Partnerships and Collaborations: Distribution by Type of Molecule
Table 32.36 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 32.37 Partnerships and Collaborations: Distribution by Type of Partner
Table 32.38 Most Active Players: Distribution by Number of Partnerships
Table 32.39 Partnerships and Collaborations: Intracontinental and Intercontinental Deals
Table 32.40 Partnerships and Collaborations: International and Local Deals
Table 32.41 Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Distribution by Range of Installed Capacity (Liters)
Table 32.42 Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Distribution by Company Size
Table 32.43 Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Distribution by Scale of Operation
Table 32.44 Global Installed Lipid Nanoparticle Contract Manufacturing Capacity: Distribution by Location of Manufacturing Facility
Table 32.45 Installed Lipid Nanoparticle Contract Manufacturing Capacity in North America
Table 32.46 Installed Lipid Nanoparticle Contract Manufacturing Capacity in Europe
Table 32.47 Installed Lipid Nanoparticle Contract Manufacturing Capacity in Asia-Pacific
Table 32.48 Global Lipid Nanoparticle Manufacturing Market, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Table 32.49 Global Lipid Nanoparticle Manufacturing Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Billion)
Table 32.50 Global Lipid Nanoparticle Manufacturing Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Billion)
Table 32.51 Lipid Nanoparticle Manufacturing Market: Distribution by Type of Lipid Nanoparticle
Table 32.52 Lipid Nanoparticle Manufacturing Market for Solid Lipid Nanoparticles, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Table 32.53 Lipid Nanoparticle Manufacturing Market for Nanostructured Lipid Carriers, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Table 32.54 Lipid Nanoparticle Manufacturing Market: Distribution by Type of Molecule Delivered
Table 32.55 Lipid Nanoparticle Manufacturing Market for Nucleic Acids, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Table 32.56 Lipid Nanoparticle Manufacturing Market for Small Molecules, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Table 32.57 Lipid Nanoparticle Manufacturing Market for Peptides / Proteins, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Table 32.58 Lipid Nanoparticle Manufacturing Market for Others, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Table 32.59 Lipid Nanoparticle Manufacturing Market: Distribution by Company Size
Table 32.60 Lipid Nanoparticle Manufacturing Market for Small Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Table 32.61 Lipid Nanoparticle Manufacturing Market for Mid-sized Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Table 32.62 Lipid Nanoparticle Manufacturing Market for Very Large and Large Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Table 32.63 Lipid Nanoparticle Manufacturing Market: Distribution by Therapeutic Area
Table 32.64 Lipid Nanoparticle Manufacturing Market for Infectious Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Table 32.65 Lipid Nanoparticle Manufacturing Market for Oncological Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Table 32.66 Lipid Nanoparticle Manufacturing Market for Blood Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Table 32.67 Lipid Nanoparticle Manufacturing Market for Rare Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Table 32.68 Lipid Nanoparticle Manufacturing Market for Other Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Table 32.69 Lipid Nanoparticle Manufacturing Market: Distribution by End-user
Table 32.70 Lipid Nanoparticle Manufacturing Market for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Table 32.71 Lipid Nanoparticle Manufacturing Market for Academic and Research Institutes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Table 32.72 Lipid Nanoparticle Manufacturing Market for Other End-users, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Table 32.73 Lipid Nanoparticle Manufacturing Market: Distribution by Key Geographical Regions
Table 32.74 Lipid Nanoparticle Manufacturing Market in North America, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Table 32.75 Lipid Nanoparticle Manufacturing Market in Europe, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Table 32.76 Lipid Nanoparticle Manufacturing Market in Asia-Pacific, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Table 32.77 Lipid Nanoparticle Manufacturing Market in Rest of the World, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Table 32.78 Revenue Shift Analysis: Key Geographical Regions
Table 32.79 Penetration Growth (P-G) Matrix: Key Geographical Regions